Tempus AI, Inc.
88.84+2.25 (+2.6%)
Oct 29, 4:00:00 PM EDT · NasdaqGS · TEM · USD
Key Stats
Market Cap
15.43BP/E (TTM)
41.32Basic EPS (TTM)
2.15Dividend Yield
0%Recent Filings
8-K
Prospectus for stock resale filed
Tempus AI filed a prospectus supplement on August 27, 2025, enabling the resale of up to 1,268,033 shares of its Class A common stock by selling stockholders. This follows an automatic shelf registration on Form S-3 initiated August 8, 2025, with a legal opinion from counsel affirming the shares' legality. The move facilitates liquidity for existing holders. No proceeds flow to the company.
10-Q
Q2 FY2025 results
Tempus AI's Q2 FY2025 revenue surged 90% y/y to $314.6M, driven by genomics jumping 115% y/y to $241.8M on higher oncology test volumes and the February 2025 Ambry acquisition adding $97.3M in hereditary testing, while data and services grew 36% y/y to $72.8M from stronger insights demand. Gross margins held steady as genomics costs rose 46% y/y with Ambry's integration, but operating loss narrowed sharply to $61.8M from $533.5M y/y, aided by lower stock-based compensation. Diluted EPS improved to -$0.25 from -$6.86 y/y, reconciling with 173.4M weighted shares. Cash dipped to $186.3M amid $380.8M in acquisitions, yet $100M revolver availability bolsters liquidity; Ambry closed for $695.3M (cash/stock), recognizing $231.2M goodwill and $399M finite-lived intangibles (3-7 years). Regulatory scrutiny in healthcare billing poses ongoing risks.
8-K
Tempus Q2 revenue soars 90%
Tempus AI crushed Q2 2025 with revenue surging 89.6% to $314.6 million, driven by genomics up 115.3% to $241.8 million on 30% clinical volume growth, while data and services rose 35.7% to $72.8 million. Gross profit leaped 158.3% to $195.0 million, narrowing adjusted EBITDA loss to $5.6 million from $31.2 million last year. Post-quarter, they issued $750 million in 0.75% convertible notes for cheaper debt. They're raising 2025 guidance to $1.26 billion revenue and $5 million adjusted EBITDA. Momentum builds.
8-K
Tempus AI upsizes convertible notes offering to $750M
Tempus AI, Inc. completed a $750 million private offering of 0.75% Convertible Senior Notes due 2030, upsized from $400 million. The notes mature on July 15, 2030, with semiannual interest payments starting January 15, 2026. Net proceeds of approximately $721.7 million will repay $274.7 million in senior secured term loans, fund $41.8 million in capped call transactions, and support general corporate purposes including acquisitions and working capital. The offering includes an over-allotment option for up to $100 million more notes.
8-K
Stockholders approve Nevada reincorporation
Tempus AI's stockholders overwhelmingly elected nine directors, including Eric Lefkofsky and Jennifer A. Doudna, at the May 20, 2025 annual meeting, with votes for exceeding 231 million across the board. They ratified PricewaterhouseCoopers as auditors for 2025, garnering 258.8 million yes votes. Crucially, they approved reincorporation from Delaware to Nevada, though the board can still scrap it. This shift promises Nevada's business-friendly laws. Directors serve until 2026.
IPO
Website
Employees
Sector
Industry
BEAT
Heartbeam, Inc.
1.60+0.01
CAI
Caris Life Sciences, Inc.
29.43-0.95
FORA
Forian Inc.
2.33-0.02
FOXO
FOXO Technologies Inc.
0.00-0.00
HWAIF
HealWELL AI Inc.
1.04-0.02
HYFT
MindWalk Holdings Corp.
1.62-0.01
OHCFF
LIGHT AI INC.
0.12-0.00
PSNL
Personalis, Inc.
9.55-0.20
SOPH
SOPHiA GENETICS SA
4.54+0.45
TDOC
Teladoc Health, Inc.
8.23-0.13